Title  | Date  | Price |
|---|
Ondansetron
Pipeline Developer
| Mar 2009 |
£2,545 |
Nebivolol
Pipeline Developer
| Mar 2009 |
£2,545 |
Omeprazole
Pipeline Developer
| Mar 2009 |
£3,440 |
Omega-3-acid ethyl esters
Pipeline Developer
| Mar 2009 |
£4,735 |
Nateglinide
Pipeline Developer
| Mar 2009 |
£2,995 |
Naratriptan
Pipeline Developer
| Mar 2009 |
£3,440 |
Octreotide
Pipeline Developer
| Mar 2009 |
£2,995 |
Pemetrexed
Pipeline Developer
| Mar 2009 |
£3,440 |
Orlistat
Pipeline Developer
| Mar 2009 |
£2,545 |
Mycophenolic Acid
Pipeline Developer
| Mar 2009 |
£2,995 |
Nicorandil
Pipeline Developer
| Mar 2009 |
£2,545 |
Olmesartan
Pipeline Developer
| Mar 2009 |
£3,885 |
Donepezil
Pipeline Developer
| Mar 2009 |
£3,440 |
Doramectin (Vet)
Pipeline Developer
| Mar 2009 |
£3,440 |
Doripenem
Pipeline Developer
| Mar 2009 |
£3,440 |
Posaconazole
Pipeline Developer
| Mar 2009 |
£3,885 |
Docetaxel
Pipeline Developer
| Mar 2009 |
£3,885 |
Desvenlafaxine
Pipeline Developer
| Mar 2009 |
£2,995 |
Olanzapine
Pipeline Developer
| Mar 2009 |
£2,995 |
Olopatadine
Pipeline Developer
| Mar 2009 |
£2,995 |
Oxaliplatin
Pipeline Developer
| Mar 2009 |
£2,995 |
Pitavastatin
Pipeline Developer
| Mar 2009 |
£3,440 |
Paclitaxel
Pipeline Developer
| Mar 2009 |
£3,885 |
European Generic Drug Market Potential
The Emergence of Generic Drug Biologics
| Feb 2009 |
£365 |
World Generic Market Report 2009
| Jan 2009 |
£595 |
Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics
2009-2023
| Jan 2009 |
£1,499 |
Nipro Medical Device Company Intelligence Report
| Nov 2008 |
£395 |
Generics: Global Industry Guide
| Nov 2008 |
£910 |
ConvaTec Medical Device Company Intelligence Report
| Oct 2008 |
£395 |
Authorized Generics
| Oct 2008 |
£205 |
Injectable Generic Drugs
Prospects & Opportunities to 2013
| Jul 2008 |
£1,295 |
Indian Bulk Drugs
| Jul 2008 |
£600 |
Generics Threats and Opportunities
Mounting an Effective Defense Strategy
| Jun 2008 |
£495 |
SpectRx, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Ventracor Limited Product Pipeline Analysis
| May 2008 |
£465 |
GE Healthcare Product Pipeline Analysis
| May 2008 |
£465 |
bioMerieux S.A. Product Pipeline Analysis
| May 2008 |
£465 |
Victhom Human Bionics Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Saliva Diagnostic Systems, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Aniara Corporation Product Pipeline Analysis
| May 2008 |
£465 |
Immunicon Corporation Product Pipeline Analysis
| May 2008 |
£465 |
Vascular Solutions, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
OMRON HEALTHCARE Co., Ltd. Product Pipeline Analysis
| May 2008 |
£465 |
AerovectRx Corporation Product Pipeline Analysis
| May 2008 |
£465 |
HandyLab, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Myocor Inc. Product Pipeline Analysis
| May 2008 |
£465 |
ABIOMED, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Viacor, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
B.R.A.H.M.S Aktiengesellschaft Product Pipeline Analysis
| May 2008 |
£465 |
Sutura, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Covidien Ltd.Tyco Healthcare Product Pipeline Analysis
| May 2008 |
£465 |
BioSyntech, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Alma Lasers, Ltd. Product Pipeline Analysis
| May 2008 |
£465 |
ES Vascular Ltd. Product Pipeline Analysis
| May 2008 |
£465 |
K2M, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Gamma Medica-Ideas, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Vivoxid Ltd. Product Pipeline Analysis
| May 2008 |
£465 |
B-Balloon Ltd. Product Pipeline Analysis
| May 2008 |
£465 |
Advanced Neuromodulation Systems, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Allergan, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Advanced Bionics Corporation Product Pipeline Analysis
| May 2008 |
£465 |
ATS Medical, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Orthofix International N.V. Product Pipeline Analysis
| May 2008 |
£465 |
Alltracel Pharmaceuticals plc Product Pipeline Analysis
| May 2008 |
£465 |
DiaSorin S.p.A Product Pipeline Analysis
| May 2008 |
£465 |
Irvine Biomedical, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Vectura Group plc Product Pipeline Analysis
| May 2008 |
£465 |
ALung Technologies, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Volcano Corporation Product Pipeline Analysis
| May 2008 |
£465 |
Osteotech, Inc. Product Pipeline Analysis
| May 2008 |
£465 |
Ziosoft Incorporated Product Pipeline Analysis
| May 2008 |
£465 |
Advanced Ocular Systems Limited Product Pipeline Analysis
| May 2008 |
£465 |
Ophthalmic Pharmaceutical Drugs
| Apr 2008 |
£2,375 |
Addressing Key Challenges in Drug Safety (Strategic Focus)
| Mar 2008 |
£2,040 |
Commercial and Pipeline Insight: Opioids
Short Acting and Anti-Abuse Technologies Set to Fragment and Grow The Market
| Mar 2008 |
£9,140 |
Opportunities and Challenges for Generic Drugs in Australia
| Mar 2008 |
£495 |
Generic League
Market Analysis and Forecasts, 2007-2012, 2017 & 2022
| Feb 2008 |
£1,999 |
Antipsychotics Market Insight & Analysis 2008
| Feb 2008 |
£1,499 |
Competitive Challenges Facing Asian Generics Producers
| Feb 2008 |
£440 |
Personalized Generics
Leveraging IT Innovation to Enable Improved Generic Drug Outcomes
| Feb 2008 |
£900 |
The Top 10 World's Leading Diagnostics Companies
| Jan 2008 |
£7,575 |
The Top 10 World's Leading Orthopedics Companies
| Jan 2008 |
£7,695 |
Cardiovascular Generic Drugs
Prospects and Opportunities to 2012
| Dec 2007 |
£995 |
Generics Series
Key Trends and Events in The 7 Major Markets
| Dec 2007 |
£2,280 |
Emerging Generic Drug Markets in Europe
| Dec 2007 |
£795 |
Pediatric Drugs: the Worldwide Market
3rd Edition
| Dec 2007 |
£2,400 |
Combating Generics
Counter-Generics Strategy, Tactics and Execution
| Dec 2007 |
£2,040 |
Consolidation in the Generic Pharmaceutical Industry
An Evolving Landscape
| Oct 2007 |
£1,250 |
Opportunities and Challenges for Generic Drugs in the UK 2007
| Jun 2007 |
£795 |
Generic Series: An Introduction to the Canadian Generics Market
Key trends and leading companies shaping the market
| Jun 2007 |
£2,280 |
Indian Bulk Drug Industry Insight 2007
| May 2007 |
£400 |
Footcare Products in the U.S.
| May 2007 |
£1,200 |
Family Planning Centers in the US
IBISWorld Industry Report
| Apr 2007 |
£390 |
2007 U.S. Drugs and Health and Beauty Aids Product Lines
| Apr 2007 |
£120 |
Generic Competition, 2007 to 2011
The impact of patent expiries on sales of major drugs
| Feb 2007 |
£1,375 |
Emerging Generic Drug Companies Worldwide 2007
| Feb 2007 |
£595 |
New Dynamics and Challenges in The Generics Market 2007
| Jan 2007 |
£1,870 |
Excipients in Pharmaceuticals
| Jan 2007 |
£2,915 |
Generics will play an increasingly important role in the pharma industry
| Oct 2006 |
£1,020 |
first
previous
